David J. Bearss

David Bearss Ph.D. is a distinguished biopharmaceutical leader with extensive experience in executive roles and board memberships across multiple organizations. As Co-Founder, CEO, President, and Chairman of the Board at Halia Therapeutics since October 2020, David also serves as Co-Founder and Chairman of Biolexis Therapeutics, Inc., and is a Board Member for BioUtah and Partner at UVB Capital. David's academic credentials include a Ph.D. in Cell and Molecular Biology from UT Health San Antonio and a Postdoctoral fellowship in Oncology and Cancer Biology. David has held advisory and directorial positions in several biotech firms, contributing to the advancement of innovative therapeutics.